Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to improved blood sugar control in ...
Zacks Investment Research on MSN
Dexcom reports positive CONNECT data for non-insulin diabetes
DexCom, Inc. DXCM recently announced positive results from its CONNECT randomized controlled trial, demonstrating that use of ...
DexCom (NasdaqGS:DXCM) reported new clinical data from its CONNECT trial on the Dexcom G7 continuous glucose monitoring system in adults with Type 2 diabetes not using insulin. The company introduced ...
DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of ...
New study results could lead to better insurance coverage of the devices for people who don’t take insulin, a researcher said ...
DexCom Inc. DXCM stock is trading higher on Monday after the diabetes management company reported positive results from its ...
The US FDA has cleared Dexcom Inc.’s Stelo over-the-counter continuous glucose monitor (CGM) for children as young as 2 years of age who do not use insulin . The Stelo Glucose Biosensor System was ...
The FDA has officially cleared the Dexcom G5 continuous glucose monitor to inform treatment decisions -- without the use of a fingerstick glucometer, other than for calibration. The G5 has been ...
Dexcom says stolen G7 sensors from two scrapped lots were sold through unauthorized channels, creating infection and reading-failure risks.
MADRID--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring (CGM), announced today the Dexcom G6 CGM System has received the CE Mark for use during pregnancy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results